MYOS Co. (NASDAQ:MYOS) Sees Significant Growth in Short Interest

MYOS Co. (NASDAQ:MYOS) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 139,300 shares, a growth of 32.8% from the May 30th total of 104,900 shares. Based on an average trading volume of 36,300 shares, the short-interest ratio is presently 3.8 days. Approximately 3.3% of the shares of the stock are short sold.

Separately, ValuEngine raised shares of WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th.

Shares of NASDAQ MYOS traded down $0.03 during mid-day trading on Friday, reaching $1.60. 3,883 shares of the company were exchanged, compared to its average volume of 59,013. MYOS has a 52 week low of $1.04 and a 52 week high of $2.02. The company has a quick ratio of 2.06, a current ratio of 3.53 and a debt-to-equity ratio of 0.04. The stock has a market cap of $14.95 million, a PE ratio of -3.56 and a beta of 0.77. The stock has a 50 day moving average of $1.42.

MYOS (NASDAQ:MYOS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. MYOS had a negative net margin of 660.40% and a negative return on equity of 86.64%. The company had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.10 million. Equities analysts anticipate that MYOS will post -0.5 EPS for the current year.

An institutional investor recently bought a new position in MYOS stock. Murphy Capital Management Inc. acquired a new position in shares of MYOS Co. (NASDAQ:MYOS) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,595 shares of the company’s stock, valued at approximately $32,000. Murphy Capital Management Inc. owned about 0.22% of MYOS as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.02% of the company’s stock.

MYOS Company Profile

MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Further Reading: The primary rules of Elliott Wave theory

Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with's FREE daily email newsletter.